Report Summary
Eternity Insights has published a new study on Global Obesity Treating Neuromodulation System Market focusing on key segments as by Type (Vagus Nerve Stimulator, Splanchnic Nerve Stimulator, Deep Brain Stimulator, Spinal Cord Stimulator, Autonomous Nerve Stimulator, Others), by Application (Hospitals, Clinics, Ambulatory Surgical Centers, Other), and by region. This deep dive re-search report highlights the market and competitive intelligence across the key segments of the mar-ket. The report also considers the impact of COVID-19 on the global Obesity Treating Neuromodulation System Market.
The report considers 2018-2020 as historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the market drivers, challenges, and trends to accurately map the market scenario and competition. Moreover, key insights related to market having direct impact on the market will also be covered.
Obesity Treating Neuromodulation System Market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
Global Obesity Treating Neuromodulation System Market Size, 2018-2028 (USD Million)
To learn more about this report
Global Obesity Treating Neuromodulation System Market Segmentation:
Obesity Treating Neuromodulation System Market, By Type
- Vagus Nerve Stimulator
- Splanchnic Nerve Stimulator
- Deep Brain Stimulator
- Spinal Cord Stimulator
- Autonomous Nerve Stimulator
- Others
Obesity Treating Neuromodulation System Market, By Application
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Other
To learn more about this report
Geographically, the market is categorized in to five regions as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America region dominates the global Obesity Treating Neuromodulation System market in terms of demand generation. The Obesity Treating Neuromodulation System market in Asia Pacific region is expected to grow at significantly high growth rate. The regional market is further sub-segmented and analyzed at granular level across key countries. The report will include market size and forecast for Obesity Treating Neuromodulation System market for below listed coun-tries across each region.
North America (U.S. and Canada), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, and Rest of Asia Pacific region); Latin America (Brazil, Mexico, and rest of the Latin America); Middle East and Africa (GCC, South Africa, and Rest of the Middle East and Africa).
Global Obesity Treating Neuromodulation System Market Taxonomy:
To learn more about this report
Global Obesity Treating Neuromodulation System Market Competitive Landscape
The global Obesity Treating Neuromodulation System market analysis report covers detailed analysis of competitive scenario across globe. The report includes profiles of leading players covering below details
- Company Overview
- Financial Analysis
- Product Portfolio Analysis
- Strategic Overview
- SWOT Analysis
List of Companies Profiled in the report:
- Medtronic
- Cyberonics
- St. Jude Medical
- BioControl Medical
- Leptos Medical
- EnteroMedics
- Nevro
- Nuvectra
- Other Players of Specific Interest can be added based on requirement
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Vagus Nerve Stimulator, Splanchnic Nerve Stimulator, Deep Brain Stimulator, Spinal Cord Stimulator, Autonomous Nerve Stimulator, Others |
| By Application Outlook |
Hospitals, Clinics, Ambulatory Surgical Centers, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Medtronic, Cyberonics, St. Jude Medical, BioControl Medical, Leptos Medical, EnteroMedics, Nevro, Nuvectra |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Benefits to the stake holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
Table Of Contents
Table of Contents
1 Study Coverage
1.1 Obesity Treating Neuromodulation System Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Obesity Treating Neuromodulation System Market Size Growth Rate by Product
1.4.2 Vagus Nerve Stimulator
1.4.3 Splanchnic Nerve Stimulator
1.4.4 Deep Brain Stimulator
1.4.5 Spinal Cord Stimulator
1.4.6 Autonomous Nerve Stimulator
1.4.7 Others
1.5 Market by End User
1.5.1 Global Obesity Treating Neuromodulation System Market Size Growth Rate by End User
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Obesity Treating Neuromodulation System Market Size
2.1.1 Global Obesity Treating Neuromodulation System Revenue 2017-2027
2.1.2 Global Obesity Treating Neuromodulation System Sales 2017-2027
2.2 Obesity Treating Neuromodulation System Growth Rate by Regions
2.2.1 Global Obesity Treating Neuromodulation System Sales by Regions
2.2.2 Global Obesity Treating Neuromodulation System Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Obesity Treating Neuromodulation System Sales by Manufacturers
3.1.1 Obesity Treating Neuromodulation System Sales by Manufacturers
3.1.2 Obesity Treating Neuromodulation System Sales Market Share by Manufacturers
3.1.3 Global Obesity Treating Neuromodulation System Market Concentration Ratio (CR5 and HHI)
3.2 Obesity Treating Neuromodulation System Revenue by Manufacturers
3.2.1 Obesity Treating Neuromodulation System Revenue by Manufacturers (2017-2020)
3.2.2 Obesity Treating Neuromodulation System Revenue Share by Manufacturers (2017-2020)
3.3 Obesity Treating Neuromodulation System Price by Manufacturers
3.4 Obesity Treating Neuromodulation System Manufacturing Base Distribution, Product Types
3.4.1 Obesity Treating Neuromodulation System Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Obesity Treating Neuromodulation System Product Type
3.4.3 Date of International Manufacturers Enter into Obesity Treating Neuromodulation System Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Obesity Treating Neuromodulation System Sales by Product
4.2 Global Obesity Treating Neuromodulation System Revenue by Product
4.3 Obesity Treating Neuromodulation System Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Obesity Treating Neuromodulation System Breakdown Data by End User
6 North America
6.1 North America Obesity Treating Neuromodulation System by Countries
6.1.1 North America Obesity Treating Neuromodulation System Sales by Countries
6.1.2 North America Obesity Treating Neuromodulation System Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Obesity Treating Neuromodulation System by Product
6.3 North America Obesity Treating Neuromodulation System by End User
7 Europe
7.1 Europe Obesity Treating Neuromodulation System by Countries
7.1.1 Europe Obesity Treating Neuromodulation System Sales by Countries
7.1.2 Europe Obesity Treating Neuromodulation System Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Obesity Treating Neuromodulation System by Product
7.3 Europe Obesity Treating Neuromodulation System by End User
8 Asia Pacific
8.1 Asia Pacific Obesity Treating Neuromodulation System by Countries
8.1.1 Asia Pacific Obesity Treating Neuromodulation System Sales by Countries
8.1.2 Asia Pacific Obesity Treating Neuromodulation System Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Obesity Treating Neuromodulation System by Product
8.3 Asia Pacific Obesity Treating Neuromodulation System by End User
9 Central & South America
9.1 Central & South America Obesity Treating Neuromodulation System by Countries
9.1.1 Central & South America Obesity Treating Neuromodulation System Sales by Countries
9.1.2 Central & South America Obesity Treating Neuromodulation System Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Obesity Treating Neuromodulation System by Product
9.3 Central & South America Obesity Treating Neuromodulation System by End User
10 Middle East and Africa
10.1 Middle East and Africa Obesity Treating Neuromodulation System by Countries
10.1.1 Middle East and Africa Obesity Treating Neuromodulation System Sales by Countries
10.1.2 Middle East and Africa Obesity Treating Neuromodulation System Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Obesity Treating Neuromodulation System by Product
10.3 Middle East and Africa Obesity Treating Neuromodulation System by End User
11 Company Profiles
11.1 Medtronic
11.1.1 Medtronic Company Details
11.1.2 Company Business Overview
11.1.3 Medtronic Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2017-2020)
11.1.4 Medtronic Obesity Treating Neuromodulation System Products Offered
11.1.5 Medtronic Recent Development
11.2 Cyberonics
11.2.1 Cyberonics Company Details
11.2.2 Company Business Overview
11.2.3 Cyberonics Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2017-2020)
11.2.4 Cyberonics Obesity Treating Neuromodulation System Products Offered
11.2.5 Cyberonics Recent Development
11.3 St. Jude Medical
11.3.1 St. Jude Medical Company Details
11.3.2 Company Business Overview
11.3.3 St. Jude Medical Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2017-2020)
11.3.4 St. Jude Medical Obesity Treating Neuromodulation System Products Offered
11.3.5 St. Jude Medical Recent Development
11.4 BioControl Medical
11.4.1 BioControl Medical Company Details
11.4.2 Company Business Overview
11.4.3 BioControl Medical Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2017-2020)
11.4.4 BioControl Medical Obesity Treating Neuromodulation System Products Offered
11.4.5 BioControl Medical Recent Development
11.5 Leptos Medical
11.5.1 Leptos Medical Company Details
11.5.2 Company Business Overview
11.5.3 Leptos Medical Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2017-2020)
11.5.4 Leptos Medical Obesity Treating Neuromodulation System Products Offered
11.5.5 Leptos Medical Recent Development
11.6 EnteroMedics
11.6.1 EnteroMedics Company Details
11.6.2 Company Business Overview
11.6.3 EnteroMedics Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2017-2020)
11.6.4 EnteroMedics Obesity Treating Neuromodulation System Products Offered
11.6.5 EnteroMedics Recent Development
11.7 Nevro
11.7.1 Nevro Company Details
11.7.2 Company Business Overview
11.7.3 Nevro Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2017-2020)
11.7.4 Nevro Obesity Treating Neuromodulation System Products Offered
11.7.5 Nevro Recent Development
11.8 Nuvectra
11.8.1 Nuvectra Company Details
11.8.2 Company Business Overview
11.8.3 Nuvectra Obesity Treating Neuromodulation System Sales, Revenue and Gross Margin (2017-2020)
11.8.4 Nuvectra Obesity Treating Neuromodulation System Products Offered
11.8.5 Nuvectra Recent Development
12 Future Forecast
12.1 Obesity Treating Neuromodulation System Market Forecast by Regions
12.1.1 Global Obesity Treating Neuromodulation System Sales Forecast by Regions 2019-2025
12.1.2 Global Obesity Treating Neuromodulation System Revenue Forecast by Regions 2019-2025
12.2 Obesity Treating Neuromodulation System Market Forecast by Product
12.2.1 Global Obesity Treating Neuromodulation System Sales Forecast by Product 2019-2025
12.2.2 Global Obesity Treating Neuromodulation System Revenue Forecast by Product 2019-2025
12.3 Obesity Treating Neuromodulation System Market Forecast by End User
12.4 North America Obesity Treating Neuromodulation System Forecast
12.5 Europe Obesity Treating Neuromodulation System Forecast
12.6 Asia Pacific Obesity Treating Neuromodulation System Forecast
12.7 Central & South America Obesity Treating Neuromodulation System Forecast
12.8 Middle East and Africa Obesity Treating Neuromodulation System Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Obesity Treating Neuromodulation System Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
